Epigenetic and metabolic programming of innate immunity in sepsis
Sepsis, the 10th leading cause of death, is the most expensive condition in the United States. The immune response in sepsis transitions from hyperinflammatory to a hypoinflammatory and immunosuppressive phase; individual variations regarding timing and overlap between hyper- and hypoinflammation ex...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Innate Immunity |
| Online Access: | https://doi.org/10.1177/1753425919842320 |
| _version_ | 1811295944467021824 |
|---|---|
| author | Vidula Vachharajani Charles E McCall |
| author_facet | Vidula Vachharajani Charles E McCall |
| author_sort | Vidula Vachharajani |
| collection | DOAJ |
| description | Sepsis, the 10th leading cause of death, is the most expensive condition in the United States. The immune response in sepsis transitions from hyperinflammatory to a hypoinflammatory and immunosuppressive phase; individual variations regarding timing and overlap between hyper- and hypoinflammation exist in a number of patients. While one third of the sepsis-related deaths occur during hyperinflammation, majority of the sepsis-mortality occurs during the hypoinflammatory phase. Currently, no phase-specific molecular-based therapies exist to treat sepsis. Coordinated epigenetic and metabolic perturbations orchestrate this shift from hyper- to hypoinflammation in innate immune cells during sepsis. These epigenetic and metabolic changes during sepsis progression and therapeutic opportunities they pose are described in this review. |
| first_indexed | 2024-04-13T05:41:03Z |
| format | Article |
| id | doaj.art-5efaf494a43b4fe89c79cff9a0396973 |
| institution | Directory Open Access Journal |
| issn | 1753-4259 1753-4267 |
| language | English |
| last_indexed | 2024-04-13T05:41:03Z |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Innate Immunity |
| spelling | doaj.art-5efaf494a43b4fe89c79cff9a03969732022-12-22T03:00:06ZengSAGE PublishingInnate Immunity1753-42591753-42672019-07-012510.1177/1753425919842320Epigenetic and metabolic programming of innate immunity in sepsisVidula VachharajaniCharles E McCallSepsis, the 10th leading cause of death, is the most expensive condition in the United States. The immune response in sepsis transitions from hyperinflammatory to a hypoinflammatory and immunosuppressive phase; individual variations regarding timing and overlap between hyper- and hypoinflammation exist in a number of patients. While one third of the sepsis-related deaths occur during hyperinflammation, majority of the sepsis-mortality occurs during the hypoinflammatory phase. Currently, no phase-specific molecular-based therapies exist to treat sepsis. Coordinated epigenetic and metabolic perturbations orchestrate this shift from hyper- to hypoinflammation in innate immune cells during sepsis. These epigenetic and metabolic changes during sepsis progression and therapeutic opportunities they pose are described in this review.https://doi.org/10.1177/1753425919842320 |
| spellingShingle | Vidula Vachharajani Charles E McCall Epigenetic and metabolic programming of innate immunity in sepsis Innate Immunity |
| title | Epigenetic and metabolic programming of innate immunity in sepsis |
| title_full | Epigenetic and metabolic programming of innate immunity in sepsis |
| title_fullStr | Epigenetic and metabolic programming of innate immunity in sepsis |
| title_full_unstemmed | Epigenetic and metabolic programming of innate immunity in sepsis |
| title_short | Epigenetic and metabolic programming of innate immunity in sepsis |
| title_sort | epigenetic and metabolic programming of innate immunity in sepsis |
| url | https://doi.org/10.1177/1753425919842320 |
| work_keys_str_mv | AT vidulavachharajani epigeneticandmetabolicprogrammingofinnateimmunityinsepsis AT charlesemccall epigeneticandmetabolicprogrammingofinnateimmunityinsepsis |